rna-writing
(2)
Amber Bio
Amber Bio is a biotechnology startup pioneering a new RNA writing platform that performs multi-kilobase edits, aiming to treat thousands of disease-causing mutations with a single product. Founded in 2021 by Jacob Borrajo and Basem Al-Shayeb out of the Broad Institute and UC Berkeley, the company launched in August 2023 with a $26M seed round co-led by Playground Global and Andreessen Horowitz Bio + Health.
Jacob Borrajo
Jacob Borrajo is the Founder and CEO of Amber Bio, a Cambridge-based biotech company pioneering a first-of-its-kind RNA writing platform capable of multi-kilobase edits. With a PhD in Biological Engineering from MIT and research training at the Broad Institute, Borrajo has spent his career building at the intersection of CRISPR, machine learning, and synthetic biology. Amber Bio launched in August 2023 with a $26 million seed round co-led by Andreessen Horowitz and Playground Global, with strategic participation from Eli Lilly and the Retinal Degeneration Fund. His platform's key innovation: treating diseases with high allelic diversity using a single therapeutic product, by editing RNA rather than DNA - making gene therapy safer, reversible, and dramatically more scalable.